|
Characteristics
|
Patients
|
OS (%)
|
Univariate analysis
|
Multivariate analysis
|
DMFS (%)
|
Univariate analysis
|
Multivariate analysis
|
|---|
|
1-year
|
3-year
|
1-year
|
3-year
|
|---|
|
Gender
|
Male
|
112
|
71.1
|
46.3
|
0.275
| |
63.1
|
38.8
|
0.568
| |
|
Female
|
15
|
66.7
|
34.6
| | |
60.0
|
35.0
| | |
|
Age, years
|
≥60
|
29
|
69.9
|
45.1
|
0.740
| |
68.7
|
48.5
|
0.558
| |
|
<60
|
98
|
70.9
|
43.2
| | |
61.2
|
35.9
| | |
|
AFP ≥100 ng/mL
|
Yes
|
74
|
63.4
|
33.4
|
0.009*
|
0.057
|
55.8
|
28.2
|
0.022*
|
0.081
|
|
No
|
53
|
80.3
|
61.1
| | |
70.2
|
52.5
| | |
|
BCLC stage
|
A
|
87
|
67.5
|
45.0
|
0.924
| |
60.6
|
37.8
|
0.934
| |
|
B
|
40
|
76.9
|
44.6
| | |
66.8
|
39.5
| | |
|
CTP class
|
A
|
111
|
74.0
|
45.3
|
0.112
| |
66.1
|
39.4
|
0.099
| |
|
B
|
16
|
60.6
|
44.6
| | |
36.1
|
27.0
| | |
|
TACE/TAE
|
Yes
|
77
|
75.5
|
50.8
|
0.047*
|
0.017*
|
66.3
|
44.3
|
0.049*
|
0.011*
|
|
No
|
50
|
62.4
|
32.9
| | |
56.8
|
26.1
| | |
|
BED10 (Gy)
|
≥100
|
44
|
87.8
|
62.0
|
0.005*
|
0.049*
|
80.2
|
50.2
|
0.006*
|
0.023*
|
|
<100
|
83
|
61.4
|
35.4
| | |
53.3
|
30.6
| | |
|
Tumor size (cm)
|
5–10
|
94
|
77.2
|
47.3
|
0.048*
|
0.137
|
67.2
|
42.0
|
0.064
|
0.053
|
|
≥10
|
33
|
51.8
|
39.1
| | |
49.8
|
28.9
| | |
|
EQD2 (Gy)
|
≥74
|
88
|
75.4
|
52.0
|
0.046*
|
0.051
|
68.0
|
46.3
|
0.008*
|
0.035*
|
|
<74
|
39
|
59.9
|
28.1
| | |
51.2
|
21.6
| | |
- CTP Child–Turcotte–Pugh, SBRT stereotactic body radiation therapy, AFP alpha fetoprotein, BED biologically effective dose, EQD
2
equivalent dose in 2Gy fraction, OS overall survival, DMFS distant metastasis-free survival, TACE/TAE trans-arterial embolization; *P < 0.05
